EP4061369A4 - A pharmaceutical form comprising acidic substance - Google Patents

A pharmaceutical form comprising acidic substance Download PDF

Info

Publication number
EP4061369A4
EP4061369A4 EP20889151.5A EP20889151A EP4061369A4 EP 4061369 A4 EP4061369 A4 EP 4061369A4 EP 20889151 A EP20889151 A EP 20889151A EP 4061369 A4 EP4061369 A4 EP 4061369A4
Authority
EP
European Patent Office
Prior art keywords
acidic substance
pharmaceutical form
pharmaceutical
acidic
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20889151.5A
Other languages
German (de)
French (fr)
Other versions
EP4061369A1 (en
Inventor
Fatih Sunel
Gulcin TOK
Selin KOKSAL UZUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2019/18013A external-priority patent/TR201918013A2/en
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP4061369A1 publication Critical patent/EP4061369A1/en
Publication of EP4061369A4 publication Critical patent/EP4061369A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
EP20889151.5A 2019-11-19 2020-10-27 A pharmaceutical form comprising acidic substance Pending EP4061369A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2019/18013A TR201918013A2 (en) 2019-11-19 2019-11-19 A pellet composition comprising propiverine or a pharmaceutically acceptable salt thereof
TR2020/16210A TR202016210A2 (en) 2019-11-19 2020-10-12 Pharmaceutical form containing acidic substance
PCT/TR2020/051001 WO2021101483A1 (en) 2019-11-19 2020-10-27 A pharmaceutical form comprising acidic substance

Publications (2)

Publication Number Publication Date
EP4061369A1 EP4061369A1 (en) 2022-09-28
EP4061369A4 true EP4061369A4 (en) 2024-04-10

Family

ID=75980705

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20889151.5A Pending EP4061369A4 (en) 2019-11-19 2020-10-27 A pharmaceutical form comprising acidic substance

Country Status (3)

Country Link
EP (1) EP4061369A4 (en)
CA (1) CA3162409A1 (en)
WO (1) WO2021101483A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579404A (en) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 Sustained-release capsule containing propiverine hydrochloride and preparation method of sustained-release capsule
CN103417544A (en) * 2012-05-22 2013-12-04 欣凯医药化工中间体（上海）有限公司 Methotrexate-folic acid compound preparation and preparation method and applications thereof
CN104546782A (en) * 2014-10-30 2015-04-29 南京科康生物科技有限公司 Lipoate enteric-coated micro-pill preparation and preparation method thereof
EP2588090B1 (en) * 2010-07-01 2017-04-19 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149674A1 (en) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
ITMI20061024A1 (en) 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd PELLETS BASED ON LIPOIC ACID

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588090B1 (en) * 2010-07-01 2017-04-19 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
CN102579404A (en) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 Sustained-release capsule containing propiverine hydrochloride and preparation method of sustained-release capsule
CN103417544A (en) * 2012-05-22 2013-12-04 欣凯医药化工中间体（上海）有限公司 Methotrexate-folic acid compound preparation and preparation method and applications thereof
CN104546782A (en) * 2014-10-30 2015-04-29 南京科康生物科技有限公司 Lipoate enteric-coated micro-pill preparation and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021101483A1 *

Also Published As

Publication number Publication date
EP4061369A1 (en) 2022-09-28
CA3162409A1 (en) 2021-05-27
WO2021101483A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
GB201911928D0 (en) Pharmaceutical compounds
EP4045480A4 (en) Pharmaceutical formulations
EP3802562A4 (en) New pharmaceutical use
GB201911944D0 (en) Pharmaceutical compounds
GB201914910D0 (en) Pharmaceutical compounds
IL289619A (en) Pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compound
IL290894A (en) Pharmaceutical formulation
IL291570A (en) Pharmaceutical compounds
EP4062938A4 (en) Combination drug
EP3890703B8 (en) Novel pharmaceutical formulation comprising a sting modulator
EP3873437A4 (en) Aqueous pharmaceutical formulations
GB201910787D0 (en) Pharmaceutical development
EP3723761A4 (en) A solid oral dosage form comprising linagliptin
EP3972607A4 (en) Pharmaceutical combination
HUE064434T2 (en) Pharmaceutical preparation
EP4061369A4 (en) A pharmaceutical form comprising acidic substance
GB201915932D0 (en) Pharmaceutical compounds
GB201915273D0 (en) Pharmaceutical compounds
GB201901989D0 (en) Pharmaceutical combinations
GB201906473D0 (en) Pharmaceutical formulation
EP3746080A4 (en) Pharmaceutical formulations
EP3697393A4 (en) Pharmaceutical dosage forms
SG10201912063PA (en) A pharmaceutical formulation
EP3903781A4 (en) Pharmaceutical preparation
EP4074313A4 (en) Solid pharmaceutical preparation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

A4 Supplementary search report drawn up and despatched

Effective date: 20240311

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/22 20060101ALI20240304BHEP

Ipc: A61K 9/20 20060101ALI20240304BHEP

Ipc: A61K 9/16 20060101ALI20240304BHEP

Ipc: A61K 9/50 20060101ALI20240304BHEP

Ipc: A61K 47/38 20060101ALI20240304BHEP

Ipc: A61P 13/10 20060101ALI20240304BHEP

Ipc: A61P 13/00 20060101ALI20240304BHEP

Ipc: A61K 31/445 20060101AFI20240304BHEP